Literature DB >> 25136898

An examination of global and regional opioid consumption trends 1980-2011.

Barbara A Hastie, Aaron M Gilson, Martha A Maurer, James F Cleary.   

Abstract

Despite expert recognition that strong opioid analgesics are the cornerstone of treatment for moderate to severe pain, most of the world's population lacks adequate availability of opioids. Moreover, great disparities in availability of opioids continue to exist between higher- and lower-to-middle-income countries. This study examined more than 30 years of consumption data reported to the International Narcotics Control Board, from 1980 to 2011, for five opioids that are indicated for the treatment of moderate to severe pain: fentanyl, hydromorphone, morphine, oxycodone, and pethidine. As such, this study offers a regional and global perspective on opioid consumption, providing an indication of preparedness for treating moderate to severe pain. Countries are categorized according to the World Health Organization's six geographical regions. Morphine equivalence (ME) statistics were calculated for each study drug, allowing for equianalgesic comparisons between consumption of the study opioids and well as the ability to aggregate all study opioids (Total ME). The ME statistic is adjusted for country population, which allows for uniform global-, regional-, and country-level equianalgesic comparisons of consumption of morphine with other opioids. Although overall trend lines revealed general increases by region, profound inequities in opioid consumption continue to abound globally.

Entities:  

Keywords:  WHO Regions; global pain disparities; opioid accessibility; opioid availability; opioid consumption; pain

Mesh:

Substances:

Year:  2014        PMID: 25136898     DOI: 10.3109/15360288.2014.941132

Source DB:  PubMed          Journal:  J Pain Palliat Care Pharmacother        ISSN: 1536-0288


  17 in total

1.  Quantifying the Adequacy of Opioid Analgesic Consumption Globally: An Updated Method and Early Findings.

Authors:  Willem K Scholten; Ann-Eva Christensen; Anne Estrup Olesen; Asbjørn Mohr Drewes
Journal:  Am J Public Health       Date:  2018-11-29       Impact factor: 9.308

Review 2.  Seizures and Meperidine: Overstated and Underutilized.

Authors:  Konrad H Schlick; Thomas M Hemmen; Patrick D Lyden
Journal:  Ther Hypothermia Temp Manag       Date:  2015-06-18       Impact factor: 1.286

3.  Opioid mortality, public health care expenditures, and cross-national homicide rates: findings from 25 OECD countries, 2000-2017.

Authors:  Alexander Testa; Douglas B Weiss; Mateus R Santos
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2021-09-30       Impact factor: 4.328

4.  Predicting the Onset of Opioid Use Disorder in the Swedish General Population.

Authors:  Kenneth S Kendler; Sara L Lönn; Jan Sundquist; Kristina Sundquist
Journal:  J Stud Alcohol Drugs       Date:  2022-05       Impact factor: 3.346

5.  A prospective study of nonmedical use of prescription opioids during adolescence and subsequent substance use disorder symptoms in early midlife.

Authors:  Sean Esteban McCabe; Philip T Veliz; Carol J Boyd; Ty S Schepis; Vita V McCabe; John E Schulenberg
Journal:  Drug Alcohol Depend       Date:  2018-11-15       Impact factor: 4.492

6.  Twenty-five years of prescription opioid use in Australia: a whole-of-population analysis using pharmaceutical claims.

Authors:  Emily A Karanges; Bianca Blanch; Nicholas A Buckley; Sallie-Anne Pearson
Journal:  Br J Clin Pharmacol       Date:  2016-05-07       Impact factor: 4.335

7.  Person-level changes in oxycodone use after the introduction of a tamper-resistant formulation in Australia.

Authors:  Andrea L Schaffer; Nicholas A Buckley; Louisa Degenhardt; Briony Larance; Rose Cairns; Timothy A Dobbins; Sallie-Anne Pearson
Journal:  CMAJ       Date:  2018-03-26       Impact factor: 8.262

8.  Prevalence and Incidence Trends for Diagnosed Prescription Opioid Use Disorders in the United Kingdom.

Authors:  Andrew J M Cooper; Jenna Willis; Janice Fuller; Heike Benecke; James Leighton-Scott; Frank Andersohn; Joseph Kim; Christoph Maier; Roger D Knaggs
Journal:  Pain Ther       Date:  2017-04-27

9.  A randomized, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients.

Authors:  Satoshi Inoue; Yoji Saito; Satoru Tsuneto; Etsuko Aruga; Hiroshi Takahashi; Mitsutoshi Uemori
Journal:  Jpn J Clin Oncol       Date:  2018-06-01       Impact factor: 3.019

10.  Risk factors for persistent and new chronic opioid use in patients undergoing total hip arthroplasty: a retrospective cohort study.

Authors:  Maria C S Inacio; Craig Hansen; Nicole L Pratt; Stephen E Graves; Elizabeth E Roughead
Journal:  BMJ Open       Date:  2016-04-29       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.